Literature DB >> 23007030

Genetic variations in hypoxia response genes influence hypertrophic cardiomyopathy phenotype.

Jaime Alkon1, Mark K Friedberg, Cedric Manlhiot, Ashok Kumar Manickaraj, Caroline Kinnear, Brian W McCrindle, Leland N Benson, Linda J Addonizio, Steven D Colan, Seema Mital.   

Abstract

BACKGROUND: Risk factors for diastolic dysfunction in hypertrophic cardiomyopathy (HCM) are poorly understood. We investigated the association of variants in hypoxia-response genes with phenotype severity in pediatric HCM.
METHODS: A total of 80 unrelated patients <21 y and 14 related members from eight families with HCM were genotyped for six variants associated with vascular endothelial growth factor A (VEGFA) downregulation, or hypoxia-inducible factor A (HIF1A) upregulation. Associations between risk genotypes and left-ventricular (LV) hypertrophy, LV dysfunction, and freedom from myectomy were assessed. Tissue expression was measured in myocardial samples from 17 patients with HCM and 20 patients without HCM.
RESULTS: Age at enrollment was 9 ± 5 y (follow-up, 3.1 ± 3.6 y). Risk allele frequency was 67% VEGFA and 92% HIF1A. Risk genotypes were associated with younger age at diagnosis (P < 0.001), septal hypertrophy (P < 0.01), prolonged E-wave deceleration time (EWDT) (P < 0.0001) and isovolumic relaxation time (IVRT) (P < 0.0001), and lower freedom from myectomy (P < 0.05). These associations were seen in sporadic and familial HCM independent of the disease-causing mutation. Risk genotypes were associated with higher myocardial HIF1A and transforming growth factor B1 (TGFB1) expression and increased endothelial-fibroblast transformation (P < 0.05).
CONCLUSION: HIF1A-upregulation and/or VEGFA-downregulation genotypes were associated with more severe septal hypertrophy and diastolic dysfunction and may provide genetic markers to improve risk prediction in HCM.

Entities:  

Mesh:

Year:  2012        PMID: 23007030     DOI: 10.1038/pr.2012.126

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  8 in total

1.  New mechanistic and therapeutic targets for pediatric heart failure: report from a National Heart, Lung, and Blood Institute working group.

Authors:  Kristin M Burns; Barry J Byrne; Bruce D Gelb; Bernhard Kühn; Leslie A Leinwand; Seema Mital; Gail D Pearson; Mark Rodefeld; Joseph W Rossano; Brian L Stauffer; Michael D Taylor; Jeffrey A Towbin; Andrew N Redington
Journal:  Circulation       Date:  2014-07-01       Impact factor: 29.690

Review 2.  Coronary arterial vasculature in the pathophysiology of hypertrophic cardiomyopathy.

Authors:  Richard J Marszalek; R John Solaro; Beata M Wolska
Journal:  Pflugers Arch       Date:  2018-10-29       Impact factor: 3.657

Review 3.  Targets for therapy in sarcomeric cardiomyopathies.

Authors:  Jil C Tardiff; Lucie Carrier; Donald M Bers; Corrado Poggesi; Cecilia Ferrantini; Raffaele Coppini; Lars S Maier; Houman Ashrafian; Sabine Huke; Jolanda van der Velden
Journal:  Cardiovasc Res       Date:  2015-01-29       Impact factor: 10.787

4.  Focal myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in children and adolescents with dilated cardiomyopathy.

Authors:  Heiner Latus; Kerstin Gummel; Karin Klingel; Axel Moysich; Markus Khalil; Nona Mazhari; Juergen Bauer; Reinhard Kandolf; Dietmar Schranz; Christian Apitz
Journal:  J Cardiovasc Magn Reson       Date:  2015-05-15       Impact factor: 5.364

5.  Serum Biomarkers of Myocardial Remodeling and Coronary Dysfunction in Early Stages of Hypertrophic Cardiomyopathy in the Young.

Authors:  E Fernlund; T Gyllenhammar; R Jablonowski; M Carlsson; A Larsson; J Ärnlöv; P Liuba
Journal:  Pediatr Cardiol       Date:  2017-03-30       Impact factor: 1.655

6.  Killing Many Birds With Two Stones: Hypoxia and Fibrosis Can Generate Ectopic Beats in a Human Ventricular Model.

Authors:  Rafael Sachetto; Sergio Alonso; Rodrigo Weber Dos Santos
Journal:  Front Physiol       Date:  2018-06-22       Impact factor: 4.566

7.  Association between genetic variants in the HIF1A-VEGF pathway and left ventricular regional myocardial deformation in patients with hypertrophic cardiomyopathy.

Authors:  Guido E Pieles; Jaime Alkon; Cedric Manlhiot; Chun-Po Steve Fan; Caroline Kinnear; Leland N Benson; Seema Mital; Mark K Friedberg
Journal:  Pediatr Res       Date:  2020-05-06       Impact factor: 3.756

8.  Vascular Endothelial Growth Factor Is Associated with the Morphologic and Functional Parameters in Patients with Hypertrophic Cardiomyopathy.

Authors:  Radek Pudil; Martina Vasatova; Alena Fucikova; Helena Rehulkova; Pavel Rehulka; Vladimir Palicka; Jiri Stulik
Journal:  Biomed Res Int       Date:  2015-12-30       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.